PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Compliance And Safety Study In Children With Upper And Lower Respiratory Tract Infections
- First Posted Date
- 2009-07-14
- Last Posted Date
- 2010-03-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 400
- Registration Number
- NCT00939185
Study Evaluating Safety and Adherence to Treatment With Etanercept in Adults With Psoriatic Arthritis
- Conditions
- Arthritis, Psoriatic
- Interventions
- Other: Questionnaire
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 303
- Registration Number
- NCT00938015
- Locations
- π§πͺ
Pfizer Investigational Site, Leuven, Belgium
A First In Human Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Single Rising Doses In Healthy Adult Volunteers
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2009-10-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT00938301
- Locations
- πΊπΈ
Pfizer Investigational Site, New Haven, Connecticut, United States
Study Evaluating Safety Of BMP-655/ACS As An Adjuvant Therapy For Rotator Cuff Repair
- Conditions
- Rotator Cuff Tear
- Interventions
- Biological: BMP-655/ACS or Standard of Care
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2012-04-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13
- Registration Number
- NCT00936559
- Locations
- π³π±
Pfizer Investigational Site, Hoofddorp, Netherlands
The Effect Of Lersivirine (UK-453,061) On Qt Intervals In Healthy Subjects
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2010-09-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 66
- Registration Number
- NCT00936871
- Locations
- π§πͺ
Pfizer Investigational Site, Bruxelles, Belgium
Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis
- Conditions
- Moderate to Severe Psoriasis
- Interventions
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2012-04-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00936065
- Locations
- π°π·
Pfizer Investigational Site, Seoul, Korea, Republic of
Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 31
- Registration Number
- NCT00935012
- Locations
- πΊπΈ
Emory University School of Medicine, Atlanta, Georgia, United States
πΊπΈThe University of Chicago Medical Center, Chicago, Illinois, United States
πΊπΈUniversity of Chicago Medical Center, Chicago, Illinois, United States
A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329
- Conditions
- Glaucoma, Open-AngleOcular Hypertension
- Interventions
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 31
- Registration Number
- NCT00934089
- Locations
- πΊπΈ
West Coast Clinical Trials, LLC, Cypress, California, United States
πΊπΈGlory Medical Group, Garden Grove, California, United States
πΊπΈEast-West Eye Institute, Los Angeles, California, United States
This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 35
- Registration Number
- NCT00932126
- Locations
- π¦πΊ
Pfizer Investigational Site, East Melbourne, Victoria, Australia
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1069
- Registration Number
- NCT00932451
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈUniversity of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
πΊπΈComprehensive Blood and Cancer Center, Bakersfield, California, United States